Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders

Background  A plasma-derived factor VIII product (pdFVIII; Factane 100 or 200 IU/mL) and a plasma-derived von Willebrand factor product (pdVWF; Wilfactin 100 IU/mL) are approved for replacement therapy by intravenous bolus injections in hemophilia A (HA) and von Willebrand disease (VWD), respectivel...

Descripción completa

Detalles Bibliográficos
Autores principales: Windyga, Jerzy, Guillet, Benoît, Rugeri, Lucia, Fournel, Alexandra, Stefanska-Windyga, Ewa, Chamouard, Valérie, Pujol, Sonia, Henriet, Céline, Bridey, Françoise, Négrier, Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393085/
https://www.ncbi.nlm.nih.gov/pubmed/35642281
http://dx.doi.org/10.1055/a-1865-6978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393085/
https://www.ncbi.nlm.nih.gov/pubmed/35642281
http://dx.doi.org/10.1055/a-1865-6978

Ejemplares similares